Potential of hydroxyebastine and terfenadine alcohol to inhibit the human cytochrome P450 2J2 isoform

Journal of the Korean Society for Applied Biological Chemistry

Volumn 54, Issue 5, 2011, Pages 659-666

  Yoon, Yune Jung ^a   Liu, Kwang Hyeon ^b,c  

^a Inje University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Kyungpook National University   (South Korea)

Author keywords

CYP2J2; Hydroxyebastine; Selective inhibitor; Terfenadine alcohol

Indexed keywords

EID: 83355164878     PISSN: 17382203     EISSN: None     Source Type: Journal    
DOI: 10.3839/jksabc.2011.101     Document Type: Article

References (36)

1. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, and Wrighton SA (2003) The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31, 815-832.
2. Chang TK, Gonzalez FJ, and Waxman DJ (1994) Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 311, 437-442.
3. Clarke SE and Jones BC (2002) Human cytochromes P450 and their role in metabolism-based drug-drug interactions. In Drug-Drug Interactions, (2nd ed.), pp. 53-86, Marcel Dekker, New York, NY.
4. Eagling VA, Tjia JF, and Back DJ (1998) Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 45, 107-114.
5. Galetin A, Clarke SE, and Houston JB (2002) Quinidine and haloperidol as modifiers of CYP3A4 activity: Multisite kinetic model approach. Drug Metab Dispos 30, 1512-1522.
6. Hutzler JM, Kolwankar D, Hummel MA, and Tracy TS (2002) Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: Kinetics and structural requirements. Drug Metab Dispos 30, 1194-1200.
7. Kim H, Yoon YJ, Shon JH, Cha IJ, Shin JG, and Liu KH (2006) Inhibitory effects of fruit juices on CYP3A activity. Drug Metab Dispos 34, 521-523.
8. Kim MJ, Kim H, Cha IJ, Park JS, Shon JH, Liu KH, and Shin JG (2005) High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 19, 2651-2658.
9. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ, and Tracy TS (1998) Evaluation of atypical cytochrome P450 kinetics with twosubstrate models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37, 4137-4147.
10. Lafite P, Andre F, Zeldin DC, Dansette PM, and Mansuy D (2007a) Unusual regioselectivity and active site topology of human cytochrome P450 2J2. Biochemistry 46, 10237-10247.
11. Lafite P, Dijols S, Buisson D, Macherey AC, Zeldin DC, Dansette PM, and Mansuy D (2006) Design and synthesis of selective, high-affinity inhibitors of human cytochrome P450 2J2. Bioorg Med Chem Lett 16, 2777-2780.
12. Lafite P, Dijols S, Zeldin DC, Dansette PM, and Mansuy D (2007b) Selective, competitive and mechanism-based inhibitors of human cytochrome P450 2J2. Arch Biochem Biophys 464, 155-168.
13. Liu KH, Kim MG, Lee DJ, Yoon YJ, Kim MJ, Shon JH, Choi CS, Choi YK, Desta Z, and Shin JG (2006) Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: Major roles for CYP2J2 and CYP3A. Drug Metab Dispos 34, 1793-1797.
14. Liu KH, Kim MJ, Jung WM, Kang W, Cha IJ, and Shin JG (2005) Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner. Drug Metab Dispos 33, 209-213.
15. Liu KH, Lee YM, Shon JH, Kim MJ, Lee SS, Yoon YR, Cha IJ, and Shin JG (2004) Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica 34, 429-438.
16. Matsumoto S, Hirama T, Kim HJ, Nagata K, and Yamazoe Y (2003) In vitro inhibition of human small intestinal and liver microsomal astemizole O-demethylation: Different contribution of CYP2J2 in the small intestine and liver. Xenobiotica 33, 615-623.
17. Muralidharan G, Hawes EM, McKay G, Korchinski ED, and Midha KK (1991) Quinidine but not quinine inhibits in man the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase. Eur J Clin Pharmacol 41, 471-474.
18. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, and Zeldin DC (2006) The human intestinal cytochrome P450 "pie". Drug Metab Dispos 34, 880-886.
19. Rendic S (2002) Summary of information on human CYP enzymes: Human P450 metabolism data. Drug Metab Rev 34, 83-448.
20. Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: Attempting to bridge the gap between cDNAexpressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57, 465-480.
21. Scarborough PE, Ma J, Qu W, and Zeldin DC (1999) P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in extrahepatic tissues. Drug Metab Rev 31, 205-234.
22. Schoch GA, Yano JK, Sansen S, Dansette PM, Stout CD, and Johnson EF (2008) Determinants of cytochrome P450 2C8 substrate binding: Structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem 283, 17227-17237.
23. Segel IH (1975) In Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems, John Wiley & Sons, Hoboken, NJ
24. Seo KA, Kim H, Ku HY, Ahn HJ, Park SJ, Bae SK, Shin JG, and Liu KH (2008) The monoterpenoids citral and geraniol are moderate inhibitors of CYP2B6 hydroxylase activity. Chem Biol Interact 174, 141-146.
25. Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV, and Korzekwa KR (1994) Activation of CYP3A4: Evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33, 6450-6455.
26. Spiecker M, Darius H, Hankeln T, Soufi M, Sattler AM, Schaefer JR, Node K, Borgel J, Mugge A, Lindpaintner K, Huesing A, Maisch B, Zeldin DC, and Liao JK (2004) Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 110, 2132-2136.
27. Stresser DM, Broudy MI, Ho T, Cargill CE, Blanchard AP, Sharma R, Dandeneau AA, Goodwin JJ, Turner SD, Erve JC, Patten CJ, Dehal SS, and Crespi CL (2004) Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible. Drug Metab Dispos 32, 105-112.
28. Taavitsainen P, Juvonen R, and Pelkonen O (2001) In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metab Dispos 29, 217-222.
29. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, and Miners JO (1994) Direct characterization of the selectivity of furafylline as an inhibitor of human cytochromes P450 1A1 and 1A2. Pharmacogenetics 4, 281-284.
30. Walsky RL and Obach RS (2003) Verification of the selectivity of (+)N-3-benzylnirvanol as a CYP2C19 inhibitor. Drug Metab Dispos 31, 343.
31. Walsky RL and Obach RS (2007) A comparison of 2-phenyl-2-(1-piperidinyl)propane (ppp), 1,1',1"-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6. Drug Metab Dispos 35, 2053-2059.
32. Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE, Maxwell BD, Chen SY, He K, Goosen TC, Humphreys WG, and Grossman SJ (2010) In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 38, 448-458.
33. Williams PA, Cosme J, Ward A, Angove HC, Matak Vinkovic D, and Jhoti H (2003) Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 424, 464-468.
34. Wu S, Chen W, Murphy E, Gabel S, Tomer KB, Foley J, Steenbergen C, Falck JR, Moomaw CR, and Zeldin DC (1997) Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem 272, 12551-12559.
35. Yuan R, Madani S, Wei XX, Reynolds K, and Huang SM (2002) Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30, 1311-1319.
36. Zeldin DC, Foley J, Goldsworthy SM, Cook ME, Boyle JE, Ma J, Moomaw CR, Tomer KB, Steenbergen C, and Wu S (1997) CYP2J subfamily cytochrome P450s in the gastrointestinal tract: Expression, localization, and potential functional significance. Mol Pharmacol 51, 931-943.